We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00948922
First Posted: July 29, 2009
Last Update Posted: October 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
July 28, 2009
July 29, 2009
October 17, 2017
June 18, 2009
July 2018   (Final data collection date for primary outcome measure)
  • Progression Free Survival (PFS) - Allogeneic Stem Cell Transplant in Multiple Myeloma Arm [ Time Frame: 2 years ]

    PFS with allogeneic stem cell transplant using melphalan+fludarabine+bortezomib as the conditioning regimen. Survival time will be measured from the date of transplant to the date of progression, death or the last follow-up, whichever comes first.

    Progressive Disease (PD): Increase of ≥ 25% from lowest response value in any one or more of the following:

    Serum M-component and/or

    Urine M-component and/or

    Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be > 10 mg/dL.

    Bone marrow plasma cell percentage; absolute percentage ≥ 10%

    Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas.

    Development of hypercalcaemia that can be attributed solely to the plasma cell proliferative disorder.

  • Progression Free Survival (PFS) - Autologous Stem Cell Transplant in Multiple Myeloma Arm [ Time Frame: 2 years ]

    PFS with autologous stem cell transplant in multiple myeloma using melphalan+bortezomib as the conditioning regimen. Survival time will be measured from the date of transplant to the date of progression, death or the last follow-up, whichever comes first.

    Progressive Disease (PD): Increase of ≥ 25% from lowest response value in any one or more of the following:

    Serum M-component and/or

    Urine M-component and/or

    Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved free light chain (FLC) levels. The absolute increase must be > 10 mg/dL.

    Bone marrow plasma cell percentage; absolute percentage ≥ 10%

    Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas.

    Development of hypercalcaemia that can be attributed solely to the plasma cell proliferative disorder.

  • progression free survival with allogeneic stem cell transplant in multiple myeloma using melphalan+fludarabine+bortezomib as the conditioning regimen [ Time Frame: two years ]
  • progression free survival with autologous stem cell transplant in multiple myeloma using melphalan+bortezomib as the conditioning regimen [ Time Frame: two years ]
Complete list of historical versions of study NCT00948922 on ClinicalTrials.gov Archive Site
  • Overall Regimen Safety [ Time Frame: 2 years ]
    Toxicity will be assessed according to Common Toxicity Criteria for Adverse Effects (CTCAE) 4.0 criteria and any grade 4 non-hematological toxicity up to 100 days will be recorded in all patients.
  • Overall Survival (OS) Rate [ Time Frame: 2 years ]
    Overall survival in patients with multiple myeloma treated with Bortezomib (Velcade®) containing conditioning regimen and autologous as well as allogeneic transplantation.
  • Molecular Complete Response (CR) Rates in Patients with Multiple Myeloma [ Time Frame: 2 years ]
    Complete Response according to International Myeloma Working Group uniform response criteria. CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow.
  • overall safety [ Time Frame: two years ]
  • overall survival [ Time Frame: two years ]
  • molecular CR rates patients with multiple myeloma [ Time Frame: two years ]
Not Provided
Not Provided
 
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.

The primary objectives of this study are:

  • To determine the 2 year-progression free survival in multiple myeloma with an allogeneic transplant using a conditioning regimen of melphalan + fludarabine + Bortezomib in patients < 60 years of age and available HLA-matched donor and compare it with the 2 year-progression-free-survival after an autologous stem cell transplant with melphalan+Bortezomib conditioning in patients < 60 years.
  • To determine the 2 year-progression free survival in multiple myeloma with an autologous stem cell transplant using a conditioning regimen of melphalan + Bortezomib. for patients > 60 years of age and patients < 60 years of age who decline allogeneic stem cell transplant.

The secondary objectives of this study are:

  • To determine the overall survival in multiple myeloma with autologous or allogeneic stem cell transplants using the above conditioning regimens
  • To determine the response rates in multiple myeloma using the above regimens.
  • To determine minimal residual disease status using allele specific oligonucleotides (ASO-PCR) by PCR and flow-cytometry for multiple myeloma cells.
  • To correlate minimal residual disease status with 2 year progression free survival and overall survival.
  • To determine the incidence of acute and chronic graft-versus-host disease (GVHD) in multiple myeloma with allogeneic stem cell transplant using the above conditioning regimen.
  • To examine quality of life in patients treated with allogeneic and autologous stem cell transplants using the above conditioning regimen.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Bortezomib
    AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
    Other Name: Velcade
  • Drug: Melphalan
    AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
    Other Name: Alkeran(R)
  • Procedure: Autologous Stem Cell Transplant
    Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Day 0 Infusion of autologous stem cells.
  • Drug: Fludarabine
    Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
    Other Name: Fludara(R)
  • Procedure: Allogeneic Stem Cell Transplant
    Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells.
  • Autologous Stem Cell Transplant
    Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
    Interventions:
    • Drug: Bortezomib
    • Drug: Melphalan
    • Procedure: Autologous Stem Cell Transplant
  • Allogeneic Stem Cell Transplant
    Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
    Interventions:
    • Drug: Bortezomib
    • Drug: Melphalan
    • Drug: Fludarabine
    • Procedure: Allogeneic Stem Cell Transplant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
124
July 2018
July 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Multiple Myeloma Criteria(International Uniform Response Criteria for Multiple Myeloma)

  • Patients with responsive disease after any line of induction therapy
  • A complete response
  • A very good partial response
  • A partial response
  • Patients greater than or equal to 18 years of age are eligible. There is upper age limit of 60 years for allogeneic transplants.
  • Patients must have a histologically confirmed diagnosis.
  • All patients should have a life expectancy of at least 12 weeks.
  • Patients must have undergone a complete psychosocial evaluation and have been considered capable of compliance.
  • Meet the following criteria for allogeneic hematopoietic cell transplant:
  • Must have an identified donor match defined as: HLA-A, HLA-B, HLA- C, DRB1 8/8 allele matched sibling, family member, or unrelated donor. [7/8 would go on separate mismatched trials] and be < 60 years of age.
  • Calculated hematopoietic cell transplantation-specific comorbidity index (HCT-CI) <3

Exclusion Criteria:

  • Patients who do not achieve at least a partial response (PR) by the criteria mentioned above with induction therapy.
  • Patient has a platelet count of <30 x 10^9/L within 14 days before enrollment.
  • Patient has >/= Grade 2 peripheral neuropathy within 30 days before enrollment.
  • Patient has an absolute neutrophil count of <1.0 x 10^9/L within 30 days before enrollment.
  • Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant in order for the subject to be considered eligible. Left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan < 40%.
  • Patient has hypersensitivity to bortezomib, boron or mannitol.
  • Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
  • Patient has received other investigational drugs with 30 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Patients with a diffusing capacity of lung for carbon monoxide (DLCO) less than 50% (adjusted) of normal or with symptomatic obstructive or restrictive lung disease are ineligible.
  • Patients with a total bilirubin greater than 2.0 mg/dL excluding Gilbert's syndrome and serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) greater than two and a half times normal (unless due to primary malignancy), or a history of severe hepatic dysfunction are ineligible.
  • Calculated creatinine clearance </= 30 ml/min within 30 days before enrollment
  • Patients with active infections are ineligible.
  • Patients who are HIV positive are ineligible.
  • Patients with active leptomeningeal involvement are ineligible. Patients with a history of previous cerebrospinal fluid (CSF) tumor involvement without symptoms or signs are eligible provided the CSF is now free of disease on lumbar puncture, and MRI of the brain shows no tumor involvement. Patients with severe symptomatic central nervous system (CNS) disease of any etiology are ineligible.
  • Patients with uncontrolled insulin-dependent diabetes mellitus defined as a random glucose level of > 400 in the 30 days prior to initiation of study therapy; or uncompensated major thyroid or adrenal dysfunction are ineligible.
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of >/= 2(Karnofsky < 50%) are ineligible.
  • Patients with an ECOG performance status of 2 to 3(Karnofsky 30-50%), secondary to bone pain, may be enrolled.
  • Patients with an ECOG performance status of 2 to 3(Karnofsky 30-50%), secondary to a potentially reversible disease-related problem, may be enrolled.
  • Patients with any previous malignancy other than non-melanoma skin cancer are ineligible, unless the patient is without evidence of disease >/= 5 years after the treatment for the cancer was completed.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00948922
MCC-15697
XO5271 ( Other Grant/Funding Number: Millennium )
Yes
Not Provided
Not Provided
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.
Principal Investigator: Melissa Alsina, MD H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP